Zachary Klaassen speaks with Adrien Holzgreve about the FLEX-MRT trial, which aims to personalize lutetium-177 PSMA radioligand therapy delivery. Currently, Pluvicto™ follows fixed dosing from the ...

ASCO 2025, prostate cancer, Metastatic Castration-Resistant Prostate Cancer (mCRPC), XALute Study, Xaluritamig, Cabazitaxel, Xaluritamig versus Cabazitaxel or Second Androgen Receptor-Directed Therapy ...

(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL between May 30 th and June 3 rd, 2025, was host to a prostate, testicular, and penile cancers ...

Interdisciplinary GU Cancer Forum 2025, non muscle invasive bladder cancer (NMIBC), Novel Agents in NMIBC, EV-104 trial, SunRISe bladder trials, TAR-200, BOND-003 trial, CREST Trial, sasanlimab, ...

SNMMI 2025 phase I trial of 61Cu-NODAGA-PSMA I&T for prostate cancer patients, prostate PET imaging, 68Ga-PSMA-11, 18F-Piflulolastat (Pylarify), and 18F-Flotufolastat (Posluma), NODAGA-PSMA I&T.

SNMMI 2025 novel PSMA-targeting drug 177Lu-P17-088, metastatic castration-resistant prostate cancer (mCRPC), VISION and PSMAfore trials, PCWG3 guidelines.

ASCO 2025, clear cell renal cell carcinoma (ccRCC), STARLITE-1 trial, 177Lu girentuximab, cabozantinib, nivolumab, 177Lu girentuximab plus cabozantinib and nivolumab, cGAS-STING pathway.

Clear explanation of what a "Foley" or indwelling catheter is, the 2 types of insertions, their use cases, and the risk of CAUTI if catheterization isn't properly managed.

SNMMI 2025, Prostate Cancer, Three-Tier Risk Stratification of Prostate Cancer by PSMA-PET PROMISE (PPP2), 8Ga versus 18F-based PSMA radiotracers.

ASCO 2025 HIF-2α targeting as a new frontier in renal cell cancer (RCC) therapy, Von Hippel-Lindau (VHL) gene mutation, LITESPARK-005, metastatic clear cell RCC. belzutifan.

(UroToday.com) The 2025 SNMMI annual meeting featured a prostate cancer and molecular imaging session and a presentation by Dr. Jiarou Wang discussing the first human study of 68 Ga-P17-079 in ...

(UroToday.com) The 2025 Interdisciplinary Genitourinary Cancer Forum featured a management of non muscle invasive bladder cancer session and a presentation by Dr. Bernard Bochner discussing clinical ...